Retinoid plus immunotherapy for lung cancer after targeted therapy fails
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a combination of a retinoid drug (all-trans retinoic acid) and an immunotherapy drug (a PD-1 inhibitor) for people with EGFR-mutant non-small cell lung cancer whose cancer has stopped responding to third-generation EGFR targeted therapy. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have been diagnosed with non-small cell lung cancer (NSCLC), the most common type of lung cancer.
- Your cancer has spread (stage IV) or has come back and cannot be treated with surgery or radiation.
- You have a specific genetic change called an EGFR mutation (like exon 19 deletion or L858R).
- You have already tried a third-generation EGFR targeted therapy (such as osimertinib) and your cancer has gotten worse.
- You are generally able to do daily activities (ECOG score of 0 or 1, or sometimes 2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for advanced non-small cell lung cancer that has stopped responding to a targeted pill (EGFR-TKI). It combines your own immune cells, grown in a lab, with another targeted pill to try to fight the cancer.
This trial tests whether giving immunotherapy again can help people with advanced non-small cell lung cancer whose disease stayed stable for at least 2 years on their first immunotherapy but then started growing. It aims to see if a second course of treatment can work again.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
This trial tests a combination of two drugs, tislelizumab and anlotinib, for people with advanced non-small cell lung cancer that has progressed after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This trial tests a combination of three targeted drugs for people with advanced non-small cell lung cancer that has a specific EGFR gene change. The goal is to see if the combination can control the cancer when previous treatments have stopped working.
This study tests a combination of two targeted therapies for non-small cell lung cancer that has continued to grow despite previous EGFR-targeted treatment. It aims to see if adding gumarontinib (a MET inhibitor) to another EGFR-targeted drug can control the cancer for longer.
Hear when a new EGFR-TKI-resistant Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.